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Abstract
Several studies have shown a negative association between smoking and primary Sjögren’s syndrome (pSS), and smoking 
may interfere with the immune response. The purpose of this study was to investigate if smoking affects disease activity and 
disease phenotype in pSS. In this cross-sectional study, consecutive pSS patients filled out the EULAR Sjögren’s Syndrome 
Patient Reported Index (ESSPRI) form and a structured questionnaire regarding smoking habits. EULAR Sjögren’s Syndrome 
Disease Activity Index (ESSDAI) scores were calculated and blood samples were analysed for type I interferon signature 
using RT-PCR. Of 90 patients (93% women, median age 66.5 years), 72% were type I IFN signature positive and 6, 42 and 
53% were current, former and never smokers, respectively. No significant differences by smoking status were found regard-
ing ESSDAI total score, activity in the ESSDAI domains or type I IFN signature. Patients with a higher cumulative cigarette 
consumption (≥ median) had higher scores in ESSPRI total [5.0 (3.0–6.3) vs 8.0 (6.0–8.3); p < 0.01] and ESSPRI sicca and 
pain domains. Comparing type I IFN signature negative and positive patients, the latter had significantly lower activity in 
ESSDAI articular domain (7/25 vs 3/64; p < 0.01) and lower scores in ESSPRI total [7.7 (5.2–8.2) vs 6.0 (4.0–7.7); p = 0.04]. 
Smoking was not associated with disease phenotype although patients with a higher cumulative cigarette consumption had 
worse symptoms in some disease domains. Current smokers were few making it difficult to draw any firm conclusions about 
associations to current smoking.
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Introduction
Primary Sjögren’s syndrome (pSS) is a chronic autoim-
mune disease that predominantly affects exocrine glands 
[1]. Affection of other organs, often termed extraglandular 
manifestations (EGM), is seen in approximately one-third 
of patients [2]. Apart from female sex, the predisposing fac-
tors leading to the development of pSS are not well known 
although genetic studies have shown associations to HLA 
class II genes and interferon-related genes [3]. Furthermore, 
viral infections and sex hormones have been suggested to 
contribute to disease development [4]. The pathogenic pro-
cess in pSS includes dysregulation of both innate and adap-
tive immunity. Both cell-mediated and humoral immunity is 
involved, the latter mirrored by hypergammaglobulinemia 
and production of anti-SSA and anti-SSB antibodies [4]. It is 
well established that type I interferons (IFNs) are important 
cytokines in the pathogenesis of pSS. The presence of an 
activated type I IFN system is commonly evaluated by ana-
lysing the expression of a selected set of type I IFN regulated 
genes. The presence of an elevated expression of these genes 
is called an “IFN-signature”. Systemic type I IFN signature 
is found in a large fraction of pSS patients [5]. The type I 
IFN signature has also been shown to be associated with 
presence of anti-SSA and anti-SSB antibodies, and hyper-
gammaglobulinemia [5]. Disease activity as evaluated by the 
European League Against Rheumatism (EULAR) Sjögren’s 
syndrome disease activity index (ESSDAI) has been asso-
ciated to type I IFN signature previously [6, 7] although 
some studies fail to confirm the association [5]. On the con-
trary, the presence of the IFN signature has been associated 
with lower patient-reported symptoms as evaluated by the 
EULAR Sjögren’s syndrome patient-reported index (ESS-
PRI) [5]. We recently published an epidemiological study 
showing that smoking was associated with a lower risk of 
later being diagnosed with pSS [8]. Similar findings have 
also been reported by others reporting a lower prevalence of 
smokers amongst pSS patients [9–11], and lower frequency 
of focal sialoadenitis [9, 11] and seropositivity for anti-SSA 
antibodies [9, 11] amongst smoking pSS patients. However, 
it is unclear whether the observed association is due to a 
local effect of smoking on the inflammation in the salivary 
glands or if smoking has an impact on systemic inflamma-
tion and consequently the phenotype of pSS.
Smoking has profound negative effects on health and 
influences the development of cardiovascular disease, 
chronic obstructive lung disease (COPD), oncogenesis 
as well as several chronic inflammatory diseases such as 
rheumatoid arthritis and Crohn’s disease [12–15]. On the 
other hand, smoking seems to ameliorate certain diseases 
such as ulcerative colitis, Behcet’s disease and Parkinson’s 
disease [16–18]. Smoking has several known effects on the 
immune system which could be important for modulation 
of chronic inflammatory diseases [19]. To the best of our 
knowledge, no other study has previously investigated the 
relation between cigarette smoking, disease phenotype and 
type I IFN signature in patients with pSS. We hypothesised 
that cigarette smoking might alter the phenotype of pSS.
In the present study, we wanted to (a) investigate the 
relation between cigarette smoking and disease activity and 
burden of symptoms and (b) investigate the relation between 
smoking and type I IFN signature in pSS patients.
Methods
Patients
Between September 2017 and May 2018, consecutive 
patients with an established diagnosis of pSS, who attended 
the out-patient clinic at the Department of Rheumatology, 
Skane University Hospital, Malmö, Sweden, were asked to 
participate in the study. Only patients above 18 years of age 
and fulfilling the American-European Consensus Group 
(AECG) criteria were included [20]. Exclusion criteria were 
concomitant fulfilment of other rheumatological diseases 
and inability of filling out the requested questionnaires due 
to mental incapacity or insufficient language skills. Patients 
underwent a physical examination and blood samples were 
drawn. Based on structured clinical evaluation and labo-
ratory analyses the ESSDAI was calculated. In addition, 
patients filled out the ESSPRI form and a structured ques-
tionnaire regarding smoking habits. None of the patients was 
using chewing tobacco. Patient characteristics are summa-
rised in Table 1.
Questionnaire on smoking habits
The questionnaire on smoking habits included questions on 
whether the patient ever had been smoking regularly and 
if the patient declared he/she had been smoking regularly, 
if he/she had quit smoking. The patient was considered a 
current smoker if answering “Yes” to the question “Have 
you ever been smoking on a regular basis?” and “No” to the 
question “Have you quit smoking?”. The patient was con-
sidered a former smoker if answering “Yes” to the question 
“Have you ever been smoking on a regular basis?” and “Yes” 
to the question “Have you quit smoking?”. Never smokers 
were defined as answering “No” to the question “Have you 
ever been smoking on a regular basis?” In case a patient 
declared ever being smoking on a regular basis, the patient 
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was asked what year he/she started and stopped smoking as 
well a question on current tobacco consumption and mean 
tobacco consumption during years of smoking. A translated 
version of the form is found in the supplementary materials 
(Supplementary material).
Patients were divided into the following groups according 
to smoking status: (1) current smokers, (2) former smok-
ers and (3) never smokers. Cigarette consumption, defined 
as pack-years was also calculated from the questionnaire. 
A pack-year is defined as twenty cigarettes smoked every 
day for one year, i.e. a cumulative consumption of 7300 
cigarettes. The average number of pack-years amongst 
ever smokers (current + former smokers) was calculated 
and patients were divided into those having a cigarette 
consumption above or equal to the median and those with a 
consumption below the median.
ESSDAI and ESSPRI
The ESSDAI index and the ESSPRI index are validated 
indices, widely used in pSS studies, and are described in 
detail elsewhere. In short, ESSDAI measures disease activ-
ity in twelve different domains where different organ sys-
tems are assessed as well as laboratory analyses mirroring 
disease activity. The total score is calculated by adding the 
individual domains scores which gives a total score ranging 
between 0 and 123. Low, moderate and high disease activity 
is defined as a score of 0–4, 5–13 and ≥ 14 respectively. In 
Table 1  Primary Sjögren’s 
syndrome patient characteristics
Data are presented as n cases/n total (%). For continuous data: mean (± SD)/median (q1–q3)
ANA anti-nuclear antibodies, C complement component, ESSDAI EULAR Sjögren’s Syndrome Disease 
Activity Index, ESSPRI EULAR Sjögren’s Syndrome Patient Reported Index, IFN interferon, IgG immu-
noglobulin G, RF rheumatoid factor
n
Females (%) 84/90 (93)
Age (years) 90 66.5 (51.8–73.0)
Current smoker (%) 5/90 (6)
 Smoke duration, years 5 48 (36.5–59.5)
 Pack-years, years 5 25 (11.3–40.2)
Former smokers (%) 37/90 (41)
 Smoke duration, years 37 17 (11.0–30.0)
 Pack-years, years 37 8.1 (3.4–17.8)
 Time since smoking cessation, years 37 27 (16–39)
 Time between smoke cessation and diagnosis, years 37 13 (6.5–21)
 Time between smoke cessation and sicca symptoms, years 17 14 (1–21)
Never smoker (%) 48/90 (53)
Ever smokers (current + former smokers) (%) 42/90 (47)
 Pack-years, years 42 8.8 (4.0–19.0)
 Smoke duration, years 42 19.5 (11.8–35.0)
Years diagnosed with pSS, years 90 13 (5.0–21.3)
Years since first sicca symptom, years 41 15 (5.0–26.0)
Anti-SSA seropositives (%) 78/90 (87)
Anti-SSB seropositives (%) 53/90 (59)
ANA seropositives (%) 70/88 (80)
RF seropositives (%) 62/88 (71)
Focal sialoadenitis (%) 62/68 (91)
IgG, g/L 89 14.8 (± 5.35)
C3, g/L 89 0.94 (± 0.21)
C4, g/l 89 0.18 (± 0.06)
ESSDAI total 89 3 (1.0–7.5)
 ESSDAI high activity 7/89 (8)
 ESSDAI moderate activity 30/89 (34)
 ESSDAI low activity 52/89 (58)
ESSPRI total 89 6.7 (4.7–8.0)
Type I IFN positive 64/89 (72)
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the ESSPRI, patients score their symptoms in three differ-
ent domains: dryness, pain, and fatigue on a Likert scale 
between 0 and 10. The total ESSPRI score is calculated as 
the mean of the different domains and thus has a range of 
0–10 [21–23].
Laboratory analyses
Blood samples were collected during routine follow-up 
appointments at office hours using a standardised (non-
fasting) procedure. Immunoglobulin (Ig)G, C3 and C4 were 
measured by nephelometry using an Immage800 (Beckham 
Coulter Inc., Brea, CA, USA). Data on the presence of rheu-
matoid factor (RF), antinuclear antibodies (ANA), anti-SSA 
and anti-SSB antibodies, all measured by validated methods 
in clinical care, is registered continuously in all pSS patients 
in our registry (Malmö Sjögren’s Syndrome Registry) and 
were not re-analysed for the current study. Currently, RF 
is measured by Phadia ImmunoCap250, anti-SSA/SSB by 
EuroblotOne, and ANA is by indirect immunoflourescence 
using HEp 2010 cells as substrate.
RT‑PCR analysis of type I IFN signature
Blood was collected in clotting tubes for serum prepara-
tion and in PAXgene RNA tubes (PreAnalytix, Hombrech-
tikon, Switzerland) for whole blood RNA analysis. Sam-
ples were stored in −  80°C until analysis. RNA isolation, 
cDNA preparation and RT-PCR were performed according 
to the manufacturer’s protocol. The protocol and selection 
of expressed genes is previously described in detail [5]. The 
type I IFN-induced genes analysed include IFI44, IFI44L, 
IFIT1, IFIT3 and MxA. Patients were divided into groups 
that were positive or negative for type I IFN using a thresh-
old of mean healthy controls (HC) + 2 S.DHC based on the 
previous analysis [5].
Statistics
Due to small sample sizes, continuous data were generally 
considered non-normally distributed and thus data is pre-
sented as median (q1–q3) and the Kruskal–Wallis test was 
used for multiple group comparisons and the Mann–Whit-
ney U test for comparison between groups. For continuous 
data including more than 80 cases, data were analysed for 
normality by visual inspection of histograms and Q–Q-plots 
and Shapiro–Wilk test. If normally distributed, data are pre-
sented as mean [± standard deviation (SD)] and the one-
way analysis of variation (ANOVA) was used for multiple 
group comparisons and the independent samples T test for 
comparison between groups. The χ2-test or Fisher’s exact 
test were used for discrete variables. Due to co-linearity of 
different variables, Bonferroni correction was not used. A 
p value < 0.05 was considered significant. The statistical 
analyses were performed using SPSS version 22 for Mac.
Results
Of 109 consecutive patients, 90 agreed to participate and 
were included in the study. Median age was 66.5 (51.8–73.0) 
years, 93% were females. In addition to fulfilling the AECG 
criteria, all patients also fulfilled the American College of 
Rheumatology (ACR)/EULAR criteria for pSS [24].
Smoking habits and IFN signatures of the study 
population
No patient declared any tobacco smoking apart from cig-
arette smoking. Six percent of pSS patients were current 
smokers, whilst 41% and 53% were former and never smok-
ers, respectively. The median time since smoke cessation 
amongst former smokers was 27 (16-39) years. The median 
cigarette consumption amongst ever smokers (former + cur-
rent smokers) was 8.8 (4.0–19.0) pack-years. 72% of pSS 
patients showed a type I IFN signature. Further characteris-
tics are found in Table 1.
Smoking habits, ESSDAI/ESSPRI and patient 
characteristics
No significant differences in ESSDAI total score or activity 
in the ESSDAI domains were found between never, former 
or current smokers, nor between patients with a cigarette 
consumption as evaluated by pack-years below vs. ≥ 8.8 
pack-years (Tables 2, 3). Comparing patients with a low 
(< 8.8 pack-years) and high (≥ 8.8 pack-years) cigarette 
consumption, a significantly higher ESSPRI total score [5.0 
(3.0–6.3) vs 8.0 (6.0–8.3); p = 0.01], ESSPRI sicca score 
[6.0 (5.0–9.0) vs 8.0 (8.0–9.0); p = 0.05] and ESSPRI pain 
score [4.0 (2.0–5.0) vs 7.0 (5.0–9.0); p = 0.01] were found 
in the high consumption group (Table 3). 
Focal sialoadenitis was present in 3/5 of current smok-
ers, and in over 90% of former smokers and never smok-
ers. Amongst former smokers, there were no significant 
differences in total ESSDAI score, presence of activity in 
the ESSDAI domains or total ESSPRI score comparing 
patients below median (27 years) and ≥ median time since 
smoke cessation (data not shown). No statistically significant 
differences in type I IFN signature positivity by smoking 
status were found (Table 2). Additionally, no statistically 
significant differences were found in levels of IgG, C3, C4, 
presence of anti-SSA, anti-SSB, ANA, or RF by smoking 
status or cigarette consumption (Tables 2, 3).
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IFN signature, ESSDAI/ESSPRI and patient 
characteristics
When studying associations between type I IFN signature 
and ESSDAI scores, only presence of activity in the ESS-
DAI articular domain was significantly lower in the type I 
IFN signature positive group in comparison with the type 
I IFN signature negative group (7/25 vs 3/64; p < 0.01). 
In addition, the ESSPRI total score [6.0 (4.0–7.7) vs 7.7 
(5.2–8.2); p = 0.04], ESSPRI sicca score [7.0 (5.0–8.0) vs 8.0 
(6.0–9.0); p = 0.03] and ESSPRI pain score [4.5 (1.3–7.0) vs 
6.0 (5.0–8.0); p = 0.02] were also significantly lower in the 
type I IFN positive group (Table 4). Type I IFN signature 
positive patients were significantly more often seropositive 
for anti-SSA (97% vs 60%; p < 0.01), anti-SSB (69% vs 32%; 
p < 0.01), ANA (89% vs 58%; p < 0.01), RF (81% vs 42%; 
p < 0.01), and had higher titers of IgG (mean 15.7 g/L; SD 
5.26 vs 12.5 g/L; SD 4.95, p = 0.01) compared to type I IFN 
signature negative patients. However, no differences in the 
presence of focal sialoadenitis, or levels of complement 3 or 
4 were found between these groups (Table 4).
Discussion
In this study, 6, 41 and 53% of the patients with pSS were 
current smokers, former smokers and never smokers, 
respectively. Seventy-two percent were type I IFN signature 
Table 2  Associations between smoking status and clinical characteristics in primary Sjögren’s syndrome patients
ANA anti-nuclear antibodies, C complement component, CNS central nervous system, ESSDAI EULAR Sjögren’s Syndrome Disease Activity 
Index, ESSPRI EULAR Sjögren’s Syndrome Patient Reported Index, IFN interferon, IgG immunoglobulin G, PNS peripheral nervous system, 
RF rheumatoid factor
*p < 0.05; data are presented as n/n total (%). For continuous data: mean (± SD)/median (q1–q3). Comparisons between the means or medians 
were performed using One-way ANOVA or Kruskal–Wallis test. Discrete variables were compared using χ2 test or Fisher’s exact test. ESSDAI 
is presented as ESSDAI total score as well as presence of activity in each ESSDAI domain. ESSPRI is presented as ESSPRI total as well as 
domain scores
Never smokers, n = 48 Former smokers, n = 37 Current smokers, n = 5 p value
ESSDAI total 3 (1.0–8.0) 4 (1.0–7.5) 1.0 (0.0–8.5) 0.55
ESSDAI activity in each domain, n (%)
 Constitutional 6/47 (13) 7/37 (19) 0/5 (0) 0.61
 Lymphadenopathy 3/47 (6) 1/37 (3) 0/5 (0) 0.71
 Glandular 5/47 (11) 5/37 (14) 0/5 (0) 0.86
 Articular 4/47 (9) 4/37 (11) 2/5 (40) 0.12
 Cutaneous 3/47 (6) 3/37 (8) 0/5 (0) 1.0
 Pulmonary 5/47 (11) 6/37 (16) 1/5 (20) 0.51
 Renal 4/47 (9) 4/37 (11) 0/5 (0) 0.83
 Muscular 0/47 (0) 1/37 (3) 0/5 (0) 0.47
 PNS 2/47 (4) 2/37 (5) 0/5 (0) 1.0
 CNS 2/47 (4) 0/37 (0) 0/5 (0) 0.56
 Haematological 11/47 (23) 8/37 (22) 0/5 (0) 0.76
 Biological 25/47 (53) 20/37 (54) 2/5 (40) 0.89
 ESSPRI total score 6.7 (4.7–7.7) 6.0 (4.5–8.0) 8.0 (6.2–8.7) 0.24
ESSPRI domain scores
 Sicca 7.0 (5.0–8.0) 8.0 (5.0–9.0) 9.0 (8.5–9.5) 0.06
 Fatigue 7.0 (5.0–8.0) 7.0 (3.0–8.0) 8.0 (4.0–9.0) 0.64
 Pain 5.0 (1.0–7.0) 5.0 (3.0–8.0) 8.0 (3.5–9.5) 0.18
Anti-SSA seropositive (%) 40/47 (85) 32/37 (87) 5/5 (100) 1.00
Anti-SSB seropositives (%) 28/47 (60) 22/37 (60) 2/5 (40) 0.78
ANA seropositives (%) 38/46 (83) 28/36 (78) 4/5 (80) 0.92
RF seropositives (%) 33/46 (72) 25/36 (69) 3/5 (60) 0.89
Focal sialoadenitis (%) 36/38 (95) 22/24 (92) 3/5 (60) 0.06
IgG (g/L) 14.4 (± 5.09) 15.7 (± 5.7) 12.8 (± 4.99) 0.40
C3 (g/L) 0.92 (± 0.19) 0.94 (± 0.23) 1.04 (± 0.29) 0.43
C4 (g/L) 0.18 (± 0.06) 0.18 (± 0.06) 0.20 (± 0.07) 0.67
Type I IFN positive (%) 33/47 (70) 29/37 (78) 2/5 (40) 0.16
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positive. A higher cumulative cigarette consumption was 
associated with higher scores in ESSPRI total and ESSPRI 
sicca and pain domains. On the contrary, type I IFN signa-
ture was associated to lower scores in ESSPRI total, and 
ESSPRI sicca and pain domains although no association was 
found between a higher cumulative cigarette consumption 
and type I IFN signature. Concerning ESSDAI scores, there 
were no associations with higher cigarette consumption, nor 
was type I IFN positivity significantly associated with ESS-
DAI-scores besides a significant negative association with 
the presence of activity in the ESSDAI articular domain.
When dividing patients into never, former and cur-
rent smokers, no significant associations were found with 
ESSDAI-scores, ESSPRI scores or type I IFN positivity. 
However, due to the low numbers of current smokers in the 
current study, caution should be taken regarding conclusions 
about the effect of current smoking.
Several previous studies [9–11, 25] have shown a negative 
association between smoking and pSS diagnosis. However, 
it is unclear whether the reported negative association is 
due to a local effect of smoking in the exocrine glands or to 
a more systemic effect. A possible explanation of the lower 
frequency of current smokers amongst pSS patients could 
be that the dryness of the oral cavity and airways increases 
the irritation of the smoke thereby making the patients more 
prone to quit smoking. Although the symptoms of dryness 
may have impact, one study comparing pSS patients with 
non-pSS sicca patients [9] and another study using data on 
Table 3  Associations between 
smoking consumption and 
clinical characteristics in 
primary Sjögren’s syndrome 
patients
ANA anti-nuclear antibodies, C complement component, CNS central nervous system, ESSDAI EULAR 
Sjögren’s Syndrome Disease Activity Index, ESSPRI EULAR Sjögren’s Syndrome Patient Reported Index, 
IFN interferon, IgG immunoglobulin G, PNS peripheral nervous system, RF rheumatoid factor
*p < 0.05; Data are presented as n/n total (%). For continuous data: mean (± SD)/median (q1–q3). Means or 
medians were compared using independent T test or Mann–Whitney U test. Discrete variables were com-
pared using χ2 test or Fisher’s exact test. ESSDAI is presented as ESSDAI total score as well as the pres-
ence of activity in each ESSDAI domain. ESSPRI is presented as ESSPRI total as well as domain scores
Pack-years < 8.8 years Pack-years ≥ 8.8 years p value
ESSDAI total 4 (1.0–7.0) 4.0 (0.0–9.0) 0.87
ESSDAI activity in each domain, n (%)
 Constitutional 3/19 (16) 4/23 (17) 1.0
 Lymphadenopathy 1/19 (5) 0/23 (0) 0.45
 Glandular 1/19 (5) 4/23 (17) 0.36
 Articular 4/19 (21) 2/23 (9) 0.38
 Cutaneous 1/19 (5) 2/23 (9) 1.0
 Pulmonary 4/19 (21) 3/23 (13) 0.68
 Renal 0/19 (0) 4/23 (17) 0.11
 Muscular 0/19 (0) 1/23 (4) 1.0
 PNS 1/19 (5) 1/23 (4) 1.0
 CNS 0/19 (0) 0/23 (0) –
 Haematological 5/19 (26) 3/23 (13) 0.43
 Biological 10/19 (53) 12/23 (52) 1.0
 ESSPRI total score 5.0 (3.0–6.3) 8.0 (6.0–8.3) 0.01*
ESSPRI domain scores
 Sicca 6.0 (5.0–9.0) 8.0 (8.0–9.0) 0.05*
 Fatigue 5.0 (2.0–8.0) 8.0 (5.0–9.0) 0.09
 Pain 4.0 (2.0–5.0) 7.0 (5.0–9.0) 0.01*
 Anti-SSA seropositive (%) 18/19 (95) 19/23 (83) 0.36
 Anti-SSB seropositives (%) 13/19 (68) 11/23 (48) 0.22
 ANA seropositives (%) 13/19 (68) 19/22 (86) 0.26
 RF seropositives (%) 12/19 (63) 16/22 (73) 0.51
 Focal sialoadenitis (%) 10/12 (83) 15/17 (88) 1.0
 IgG (g/L) 15.9 (± 6.98) 14.9 (± 4.50) 0.68
 C3 (g/L) 0.94 (± 0.25) 0.97 (± 0.24) 0.73
 C4 (g/L) 0.19 (± 0.08) 0.19 (± 0.05) 0.98
 Type I IFN positive (%) 15/19 (79) 16/23 (70) 0.73
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smoking acquired years before the individuals were diag-
nosed with pSS [8] still found a lower frequency of current 
smokers amongst pSS patients which may indicate that dry-
ness might not be the only explanation. In the current study, 
we investigated whether smoking habits is associated with 
the phenotypic expression of pSS. We did not find any evi-
dence that previous smoking alters the phenotype of pSS, 
neither as evaluated by ESSDAI-scores nor by type I IFN 
signature. The higher ESSPRI sicca and pain domain scores 
amongst patients with a higher cumulative cigarette con-
sumption (≥ 8.8 packyears) do signal a long term effect by 
smoking. E.g. long term smoking has previously been shown 
to be associated to reduced amount and quality of saliva [26] 
why harmful effects on the salivary glands, not affecting 
the development of pSS, might be an explanation for the 
increased sicca symptoms. Furthermore, there are previous 
reports of smoking being a risk factor for chronic pain [27], 
and thus the higher scores in ESSPRI pain amongst patients 
with higher cumulative cigarette consumption might not be 
associated with pSS disease activity.
Current smokers in this cohort of consecutive patients 
were too few to make any conclusions regarding this group. 
It would be of interest to study a larger group of current 
smoking pSS patients to investigate if the numerical dif-
ferences seen in some of the ESSDAI scores and ESSPRI 
scores in this study (Table 2) can be reproduced, especially 
since cigarette smoking has been shown to suppress IFN I 
signalling [28].
We did not find any association between type I IFN signa-
ture and ESSDAI total score in the current cohort although 
there was a significantly lower prevalence of activity in the 
ESSDAI articular domain amongst type I IFN signature 
positive patients. Previous studies have shown that the asso-
ciation between the type I IFN signature and the ESSDAI 
varies between studied cohorts [5–7]. This could be due to 
the insufficient sensitivity of the ESSDAI to tap systemic 
inflammation or that the systemic inflammation measured 
by ESSDAI is not solely driven by type I IFN [29, 30]. How-
ever, previously demonstrated associations between type I 
IFN signature, autoantibodies and hypergammaglobulinemia 
in two previous pSS cohorts [5] were reproduced in the cur-
rent pSS cohort.
Concerning symptoms, we found an inverse association 
between type I IFN signature and ESSPRI total, sicca and 
pain scores. A negative association between ESSPRI and 
IFN signature and other proinflammatory cytokines has pre-
viously been described [5, 31]. A possible explanation for 
this finding could be that the mechanisms regulating inflam-
mation also affect symptoms such as fatigue and pain as 
proposed by Howard Tripp et al. [31]. There are also reports 
that IFNα inhibits nociceptive transmission in the spinal 
cord which could provide an explanation to the negative 
association between type I IFN signature and the ESSDAI 
pain domain [32]. Furthermore, there are also reports that 
treatment with low dose IFNα improves salivary flow in pSS 
patients [33], which can be due to an increased expression 
of the aquaporine-5 gene [34].
Strengths of the current study include the use of con-
secutive, well-characterised patients in routine clinical 
care. However, there were several limitations of the study: 
Smoking exposure in this cohort of consecutive patients 
Table 4  Clinical characteristics stratified on type I interferon activa-
tion
ANA anti-nuclear antibodies, C complement component, CNS cen-
tral nervous system, ESSDAI EULAR Sjögren’s Syndrome Dis-
ease Activity Index, ESSPRI EULAR Sjögren’s Syndrome Patient 
Reported Index, IFN interferon, IgG immunoglobulin G, PNS periph-
eral nervous system, RF rheumatoid factor
*p < 0.05; data are presented as n/n total (%). For continuous data: 
mean (± SD)/median (q1–q3). Independent T test for continuous, nor-
mally distributed variables, Means or medians were compared using 
independent T test or Mann–Whitney U test. Discrete variables were 
compared using χ2 test or Fisher’s exact test. ESSDAI is presented 
as an ESSDAI total scores as well as the presence of activity in each 
ESSDAI domain. ESSPRI is presented as ESSPRI total as well as 
domain scores
IFN I neg, n = 25 IFN I pos, n = 64 p value
ESSDAI total score 3.0 (0.0–8.0) 3.0 (1.0–7.8) 0.85
ESSDAI activity in each domain
 Constitutional 5/25 (20) 8/64 (13) 0.50
 Lymphadenopaty 1/25 (4) 3/64 (5) 1.0
 Glandular 2/25 (8) 8/64 (13) 0.72
 Articular 7/25 (28) 3/64 (5) < 0.01*
 Cutaneous 2/25 (8) 4/64 (6) 1.0
 Pulmonary 1/25 (4) 11/64 (17) 0.17
 Renal 2/25 (8) 6/64 (9) 1.0
 Muscular 0/25 (0) 1/64 (2) 1.0
 PNS 1/25 (4) 3/64 (5) 1.0
 CNS 1/25 (4) 1/64 (2) 0.49
 Haematological 4/25 (16) 15/64 (23) 0.44
 Biological 13/25 (52) 34/64 (53) 0.92
 ESSPRI total score 7.7 (5.2–8.2) 6.0 (4.0–7.7) 0.04*
ESSPRI domain scores
 Sicca 8.0 (6.0–9.0) 7.0 (5.0–8.0) 0.03*
 Fatigue 8.0 (5.0–9.0) 7.0 (5.0–8.0) 0.26
 Pain 6.0 (5.0–8.0) 4.5 (1.3–7.0) 0.02*
 Anti-SSA seroposi-
tives
15/25 (60) 62/64 (97) < 0.01*
 Anti-SSB seroposi-
tives
8/25 (32) 44/64 (69) < 0.01*
 ANA seropositives 14/24 (58) 56/63 (89) < 0.01*
 RF seropositives 10/24 (42) 51/63 (81) < 0.01*
 Focal sialoadenitis 16/18 (89) 45/49 (92) 0.66
 IgG (g/L) 12.5 (± 4.95) 15.7 (± 5.26) 0.01*
 C3 (g/L) 0.94 (± 0.21) 0.93 (± 0.22) 0.83
 C4 (g/L) 0.19 (± 0.07) 0.18 (± 0.06) 0.42
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was mostly long before the study started and the amount of 
consumed cigarettes varied a lot. Therefore, the population 
of ever smokers and former smokers was heterogenous. As 
expected, the number of current smokers was low, making it 
difficult to draw conclusions about the association to current 
smoking. However, the prevalence of daily smokers in the 
general population has reduced [35]. Therefore, it might be 
difficult to include a larger number of current daily smokers 
in future studies. Retrospectively acquired data on smoking 
also has limitations due to recall bias. It is also possible that 
patients might interpret certain questions in the question-
naire differently such as whether they have been smoking 
regularly. Potential confounders of sicca symptoms, e.g. use 
of antidepressants or other drugs with anti-cholinergic side 
effects, were not available. Most patients had long-standing 
pSS, and we cannot exclude that different patterns may be 
observed in patients with recent onset of clinical disease.
Conclusion
Patients with a higher cumulative smoking exposure scored 
significantly higher in ESSPRI total, and ESSPRI sicca and 
pain domains scores whilst type I IFN signature positive 
patients scored significantly lower in ESSPRI total, sicca 
and pain domains. No difference in type I IFN positivity was 
found between the group of high and low cumulative ciga-
rette consumption nor were there any differences in ESSDAI 
total score or activity in the ESSDAI domains.
No significant differences were found between never, for-
mer or current smokers in ESSDAI scores, ESSPRI scores 
or type I IFN positivity. Of note, current smokers were few 
in this study making it difficult to draw any firm conclusions 
regarding this group.
In conclusion, there does not seem to be a strong and 
consistent association between former smoking and disease 
activity, patient-reported symptoms or laboratory signs of 
systemic inflammation in pSS, at least not in established 
disease. A higher cumulative consumption of cigarettes is 
associated with more symptoms although this might have 
other explanations than pSS disease activity.
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